- Home
- FOR vs CVAC Comparison
FOR vs CVAC Comparison
Compare FOR & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOR
- CVAC
- Stock Information
- Founded
- FOR 2005
- CVAC 2000
- Country
- FOR United States
- CVAC Germany
- Employees
- FOR N/A
- CVAC N/A
- Industry
- FOR Real Estate
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- FOR Finance
- CVAC Health Care
- Exchange
- FOR Nasdaq
- CVAC Nasdaq
- Market Cap
- FOR 1.0B
- CVAC 1.2B
- IPO Year
- FOR 2007
- CVAC 2020
- Fundamental
- Price
- FOR $27.07
- CVAC $5.35
- Analyst Decision
- FOR Strong Buy
- CVAC Hold
- Analyst Count
- FOR 4
- CVAC 3
- Target Price
- FOR $30.25
- CVAC $6.83
- AVG Volume (30 Days)
- FOR 137.0K
- CVAC 473.7K
- Earning Date
- FOR 10-28-2025
- CVAC 11-11-2025
- Dividend Yield
- FOR N/A
- CVAC N/A
- EPS Growth
- FOR N/A
- CVAC N/A
- EPS
- FOR 3.19
- CVAC 1.01
- Revenue
- FOR $1,543,300,000.00
- CVAC $599,540,810.00
- Revenue This Year
- FOR $3.62
- CVAC N/A
- Revenue Next Year
- FOR $7.99
- CVAC $23.95
- P/E Ratio
- FOR $8.40
- CVAC $5.33
- Revenue Growth
- FOR 2.35
- CVAC 675.15
- 52 Week Low
- FOR $18.00
- CVAC $2.37
- 52 Week High
- FOR $34.82
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- FOR 49.64
- CVAC 44.68
- Support Level
- FOR $27.40
- CVAC $5.34
- Resistance Level
- FOR $28.25
- CVAC $5.41
- Average True Range (ATR)
- FOR 0.76
- CVAC 0.04
- MACD
- FOR -0.27
- CVAC -0.00
- Stochastic Oscillator
- FOR 14.12
- CVAC 33.33
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.